DE60110244D1 - Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose-nukleotide - Google Patents

Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose-nukleotide

Info

Publication number: DE60110244D1
Authority: DE; Germany
Prior art keywords: arabinonucleotide; residues; antisense oligonucleotides; flanking; series
Prior art date: 2000-09-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60110244T

Other languages

English (en)

Other versions

DE60110244T2 (de

Inventor

Jose Damha

A Parniak

Chun-Nam Lok

Ekaterina Viazovkina

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

McGill University

Original Assignee

McGill University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-06

Filing date

2001-09-04

Publication date

2005-05-25

2001-09-04 Application filed by McGill University filed Critical McGill University

2005-05-25 Application granted granted Critical

2005-05-25 Publication of DE60110244D1 publication Critical patent/DE60110244D1/de

2006-01-19 Publication of DE60110244T2 publication Critical patent/DE60110244T2/de

2021-09-05 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical class OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 title abstract 4
108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 3
239000000074 antisense oligonucleotide Substances 0.000 title abstract 3
238000012230 antisense oligonucleotides Methods 0.000 title abstract 3
HMFHBZSHGGEWLO-HWQSCIPKSA-N L-arabinofuranose Chemical class OC[C@@H]1OC(O)[C@H](O)[C@H]1O HMFHBZSHGGEWLO-HWQSCIPKSA-N 0.000 title 1
239000002214 arabinonucleotide Substances 0.000 abstract 6
108020004394 Complementary RNA Proteins 0.000 abstract 2
108091034117 Oligonucleotide Proteins 0.000 abstract 2
239000003184 complementary RNA Substances 0.000 abstract 2
108020000999 Viral RNA Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
230000000692 anti-sense effect Effects 0.000 abstract 1
230000001413 cellular effect Effects 0.000 abstract 1
238000003776 cleavage reaction Methods 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
108020004999 messenger RNA Proteins 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
230000007017 scission Effects 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
230000035897 transcription Effects 0.000 abstract 1
238000013518 transcription Methods 0.000 abstract 1
230000014616 translation Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Public Health (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

DE60110244T 2000-09-06 2001-09-04 Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribosenukleotide Expired - Lifetime DE60110244T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US23041400P	2000-09-06	2000-09-06
US230414P		2000-09-06
PCT/CA2001/001252 WO2002020773A2 (en)	2000-09-06	2001-09-04	Chimeric antisense oligonucleotides of arabinofuranose analogues and deoxyribose nucleotides

Publications (2)

Publication Number	Publication Date
DE60110244D1 true DE60110244D1 (de)	2005-05-25
DE60110244T2 DE60110244T2 (de)	2006-01-19

Family

ID=22865132

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60110244T Expired - Lifetime DE60110244T2 (de)	2000-09-06	2001-09-04	Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribosenukleotide

Country Status (8)

Country	Link
US (1)	US8178348B2 (de)
EP (1)	EP1315807B1 (de)
JP (1)	JP2004507272A (de)
AT (1)	ATE293688T1 (de)
AU (2)	AU8944801A (de)
CA (1)	CA2419563C (de)
DE (1)	DE60110244T2 (de)
WO (1)	WO2002020773A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4595399A (en) *	1998-06-19	2000-01-10	Mcgill University	Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
MXPA04007403A (es) *	2002-02-01	2005-07-01	Univ Mcgill	Oligonucleotidos que comprenden segmentos alternos y usos de los mismos.
US20050053981A1 (en) *	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
MX2007005083A (es)	2004-10-29	2007-10-03	Topigen Pharmaceuticals Inc	Oligonucleotidos antisentido para tratar alergias y proliferacion celular neoplastica.
BRPI0713111A2 (pt)	2006-05-19	2012-04-17	Topigen Pharmaceuticals Inc	oligonucleotìdeos que afetam a expressão das fosfodiesterases
US8470999B2 (en)	2008-05-15	2013-06-25	Luc Paquet	Oligonucleotides for treating inflammation and neoplastic cell proliferation
CN107083386A (zh) *	2008-08-25	2017-08-22	埃克斯雷德制药有限公司	阻止结缔组织生长因子的反义核苷酸及其用途
GB201110239D0 (en) *	2011-06-17	2011-08-03	College The	Labelling method
WO2013040429A1 (en)	2011-09-14	2013-03-21	Rana Therapeutics Inc.	Multimeric oligonucleotide compounds
WO2014043544A1 (en)	2012-09-14	2014-03-20	Rana Therapeutics, Inc.	Multimeric oligonucleotide compounds
CN112969799A (zh) *	2018-09-26	2021-06-15	奥姆生命科技公司	2′fana修饰的foxp3反义寡核苷酸及其使用方法
EP3861118A4 (de) *	2018-10-05	2023-11-15	Ionis Pharmaceuticals, Inc.	Modifizierte oligomere verbindungen und verwendungen davon
TW202042822A (zh)	2019-01-22	2020-12-01	美商科羅生物公司	Rna編輯之寡核苷酸及其用途
AU2020210900B2 (en) *	2019-01-22	2025-04-24	Korro Bio, Inc.	RNA-editing oligonucleotides and uses thereof
US11453878B2 (en)	2019-01-22	2022-09-27	Korro Bio, Inc.	RNA-editing oligonucleotides and uses thereof
CA3151789A1 (en) *	2019-09-19	2021-03-25	Arnay Sciences, Llc	Compounds and methods useful for modulating gene splicing
CN118660964A (zh) *	2021-12-16	2024-09-17	瓦莱里奥治疗公司	新型缀合核酸分子及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5955589A (en) *	1991-12-24	1999-09-21	Isis Pharmaceuticals Inc.	Gapped 2' modified oligonucleotides
US5808040A (en) *	1995-01-30	1998-09-15	Yale University	L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5968748A (en) *	1998-03-26	1999-10-19	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of human HER-2 expression
US20010049436A1 (en) *	1998-04-01	2001-12-06	Wen-Qiang Zhou	Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
AU4595399A (en) *	1998-06-19	2000-01-10	Mcgill University	Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues

2001
- 2001-09-04 EP EP01969101A patent/EP1315807B1/de not_active Expired - Lifetime
- 2001-09-04 AU AU8944801A patent/AU8944801A/xx active Pending
- 2001-09-04 CA CA2419563A patent/CA2419563C/en not_active Expired - Lifetime
- 2001-09-04 JP JP2002525780A patent/JP2004507272A/ja active Pending
- 2001-09-04 AU AU2001289448A patent/AU2001289448B8/en not_active Ceased
- 2001-09-04 AT AT01969101T patent/ATE293688T1/de not_active IP Right Cessation
- 2001-09-04 WO PCT/CA2001/001252 patent/WO2002020773A2/en not_active Ceased
- 2001-09-04 US US10/363,768 patent/US8178348B2/en not_active Expired - Fee Related
- 2001-09-04 DE DE60110244T patent/DE60110244T2/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ATE293688T1 (de)	2005-05-15
AU8944801A (en)	2002-03-22
CA2419563C (en)	2018-03-20
DE60110244T2 (de)	2006-01-19
US20040038399A1 (en)	2004-02-26
EP1315807A2 (de)	2003-06-04
JP2004507272A (ja)	2004-03-11
US8178348B2 (en)	2012-05-15
AU2001289448B8 (en)	2006-08-10
WO2002020773A2 (en)	2002-03-14
WO2002020773A3 (en)	2003-01-23
EP1315807B1 (de)	2005-04-20
CA2419563A1 (en)	2002-03-14
AU2001289448B2 (en)	2006-03-16

Publication	Publication Date	Title
DE60110244D1 (de)	2005-05-25	Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose-nukleotide
DE69934227D1 (de)	2007-01-11	Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
Iwai et al.	1992	Recognition of the high affinity binding site in rev-response element RNA by the human immunodeficiency virus type-1 rev protein
Cohen	1991	Antisense oligodeoxynucleotides as antiviral agents
WO2004015075A3 (en)	2004-06-17	SHORT INTERFERING RNAs HAVING A HAIRPIN STRUCTURE CONTAINING A NON-NUCLEOTIDE LOOP
TNSN08252A1 (en)	2009-10-30	Sirna anti myosine va et depigmentation de la peau
Patel et al.	1996	Formation of chimeric DNA primer extension products by template switching onto an annealed downstream oligonucleotide.
Matteucci et al.	1991	Deoxyoligonucleotides bearing neutral analogs of phosphodiester linkages recognize duplex DNA via triple-helix formation
JP2003219893A5 (de)	2006-03-02
WO2003101386A3 (en)	2004-10-07	Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
WO2001083513A3 (en)	2002-05-23	Antisense modulation of inhibitor of dna binding-1 expression
PODDEVIN et al.	1994	Improved Anti-Herpes Simplex Virus Type 1 Activity of a Phosphodiester Antisense Oligonucleotide Containing a 3′ al Hairpin-Like Structure
KR20040028771A (ko)	2004-04-03	비시엘-2 디엔에이 효소
WO2000008140A3 (en)	2000-05-18	Antisense oligonucleotides for the inhibition of vegf expression
WO1996035706A1 (en)	1996-11-14	Pyrimidine targeting hairpin triplex-forming oligonucleotides
EP1697498A4 (de)	2007-10-31	Kinasesuppressor der ras-inaktivierung zur therapie von durch ras vermittelter tumorgenese
DE602004031946D1 (de)	2011-05-05	Das künstliche cpg single strand deoxidation-oligonukleotid und dessen antivirale anwendungen
WO2003031459A3 (de)	2003-11-13	Modulation der expression stat-1-abhängiger gene
Yamakawa et al.	1998	Properties of nicked and circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligodeoxynucleotides
EP1073731B1 (de)	2007-12-19	Nukleinsäure-enzym zur spaltung von rna
CA2331333A1 (en)	1999-12-29	Antisense oligonucleotide constructs based on .beta.-arabinofuranose and its analogues
JP2006514546A5 (de)	2006-12-28
IT1320168B1 (it)	2003-11-18	Oligonucleotidi sintetici in grado di indurre il differenziamentoeritroide.
TEMSAMANI et al.	1994	Inhibition of in vitro transcription by oligodeoxynucleotides
CA2330570C (en)	2010-01-12	Nucleic acid enzyme for rna cleavage

Legal Events

Date	Code	Title	Description
2006-05-24	8364	No opposition during term of opposition